IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.021
EU - Europa 3.888
AS - Asia 3.851
Continente sconosciuto - Info sul continente non disponibili 479
SA - Sud America 417
AF - Africa 67
OC - Oceania 8
Totale 15.731
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.881
SG - Singapore 1.452
CN - Cina 1.145
IT - Italia 640
UA - Ucraina 532
IE - Irlanda 508
GB - Regno Unito 442
RU - Federazione Russa 398
TR - Turchia 369
SE - Svezia 368
VN - Vietnam 365
FR - Francia 342
BR - Brasile 339
DE - Germania 235
FI - Finlandia 141
IN - India 134
PL - Polonia 127
BD - Bangladesh 97
HK - Hong Kong 77
CA - Canada 68
MX - Messico 46
ES - Italia 33
JP - Giappone 33
ZA - Sudafrica 31
AR - Argentina 30
SA - Arabia Saudita 28
CZ - Repubblica Ceca 27
BE - Belgio 24
IQ - Iraq 21
ID - Indonesia 19
KR - Corea 19
NL - Olanda 19
AT - Austria 15
PK - Pakistan 13
AE - Emirati Arabi Uniti 12
LT - Lituania 12
UZ - Uzbekistan 11
EC - Ecuador 10
VE - Venezuela 10
IR - Iran 9
MA - Marocco 9
CO - Colombia 8
JM - Giamaica 8
CL - Cile 7
PH - Filippine 7
AU - Australia 6
MY - Malesia 6
BY - Bielorussia 5
EU - Europa 5
JO - Giordania 5
LY - Libia 5
AZ - Azerbaigian 4
DZ - Algeria 4
EG - Egitto 4
HN - Honduras 4
KE - Kenya 4
PS - Palestinian Territory 4
PY - Paraguay 4
RO - Romania 4
TN - Tunisia 4
UY - Uruguay 4
CH - Svizzera 3
GR - Grecia 3
GT - Guatemala 3
IL - Israele 3
KZ - Kazakistan 3
NP - Nepal 3
OM - Oman 3
PE - Perù 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
BN - Brunei Darussalam 2
GA - Gabon 2
HU - Ungheria 2
LB - Libano 2
NI - Nicaragua 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GP - Guadalupe 1
GY - Guiana 1
HR - Croazia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
SC - Seychelles 1
SN - Senegal 1
TO - Tonga 1
Totale 15.259
Salva come PNG Salva come JPEG
Città #
Singapore 1.074
San Jose 751
Chandler 662
Jacksonville 584
Dublin 499
Ashburn 462
Dallas 354
Southend 312
Beijing 291
Council Bluffs 269
Princeton 220
Dearborn 182
Izmir 170
Los Angeles 167
Nanjing 155
Ho Chi Minh City 117
New York 102
Wilmington 101
Kraków 98
Cambridge 96
Hanoi 90
Santa Clara 90
Chieti 89
Tongling 84
Altamura 79
Hong Kong 72
The Dalles 71
Ann Arbor 67
Nanchang 64
Boardman 55
Phoenix 53
Buffalo 52
Munich 50
Moscow 44
Columbus 42
Shenyang 42
São Paulo 41
Woodbridge 38
Orem 37
Redondo Beach 34
Rome 33
Atlanta 32
Denver 32
Changsha 29
Hebei 29
Pescara 29
Tianjin 29
Hefei 28
Grevenbroich 27
Helsinki 27
Houston 27
Warsaw 27
Montreal 26
Washington 26
Jiaxing 25
Chicago 24
Seattle 24
Brooklyn 23
Riyadh 23
Tokyo 23
Brno 22
Brussels 21
Kocaeli 21
Hangzhou 20
Johannesburg 20
Kunming 20
Camerino 19
San Francisco 19
St Louis 19
Mexico City 18
Seoul 18
Shanghai 18
Orange 17
Toronto 17
Milan 16
Norwalk 16
Spoltore 16
Boston 15
Da Nang 15
Manchester 15
Nuremberg 15
Poplar 15
Lappeenranta 14
Stockholm 14
Belo Horizonte 13
Chennai 13
Jinan 13
Mumbai 13
Ankara 12
Düsseldorf 12
Haiphong 12
Frankfurt am Main 11
Guangzhou 11
Leawood 11
London 11
Rio de Janeiro 11
Lanzhou 10
Amsterdam 9
Dong Ket 9
Hải Dương 9
Totale 9.003
Salva come PNG Salva come JPEG
Nome #
Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease 599
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 319
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 274
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 248
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 219
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 191
Antithrombotic Agents and Cancer 184
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 177
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 172
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 167
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 166
Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained 164
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 158
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 158
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 158
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 154
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 154
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 152
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 148
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 146
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 145
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 143
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 140
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 140
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 138
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 137
New insights into COX-2 biology and inhibition. 135
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 135
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 134
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 133
Oxidative stress and platelet activation in essential hyperytension 132
Determinants of platelet activation in human essential hypertension. 132
Clinical pharmacology of selective COX-2 inhibitors. 131
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 130
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 129
Platelet activation in patients with colorectal cancer. 129
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 128
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 128
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 127
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 126
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 125
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 125
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 124
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 124
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 124
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 124
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 124
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 124
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 123
Gut microbiota, host gene expression, and aging. 123
Risk management profile of etoricoxib: An example of personalized medicine 123
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 123
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 122
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 121
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 121
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 121
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 121
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 121
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 120
Clinical pharmacology of novel selective COX-2 inhibitors. 120
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 120
Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk 119
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 119
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 118
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 118
Mechanistic and pharmacological issues of aspirin as an anticancer agent 118
NSAIDs and cardiovascular disease. 118
New antiplatelet approach: inhibiting Pim kinase to reduce constitutive surface expression of thromboxane A2 receptor 117
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 117
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 117
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 117
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 115
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 113
Clinical pharmacology of etoricoxib. 113
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 111
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 111
Pharmacodynamic of cyclooxygenase inhibitors in humans. 110
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 110
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 108
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 108
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 108
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 107
Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention 105
Characterization of the acetylation of cyclooxygenase-isozymes and targeted lipidomics of eicosanoids in serum and colon cancer cells by the new aspirin formulation IP1867B versus aspirin in vitro 105
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 104
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 104
Cyclooxygenases and platelet functions 103
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 103
P2Y12 Receptors in Tumorigenesis and Metastasis 103
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 102
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 102
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 102
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 100
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 99
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 98
Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity 96
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 96
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 96
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 96
Evaluating plasma vesicle signatures in chronic coronary artery disease patients for tailored dual therapy with low-dose rivaroxaban and aspirin 95
Totale 13.554
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.026
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.026
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022471 0 0 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.792 123 272 198 43 52 98 66 141 152 98 219 330
2025/20265.617 443 250 526 672 471 307 829 328 558 430 315 488
2026/20271.072 332 631 109 0 0 0 0 0 0 0 0 0
Totale 15.731